Caxton Associates LLP Cytek Biosciences, Inc. Transaction History
Caxton Associates LLP
- $4.11 Billion
- Q3 2025
A detailed history of Caxton Associates LLP transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 93,408 shares of CTKB stock, worth $513,744. This represents 0.01% of its overall portfolio holdings.
Number of Shares
93,408
Previous 103,465
9.72%
Holding current value
$513,744
Previous $352 Million
99.91%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding CTKB
# of Institutions
151Shares Held
73MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$93.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.93MShares$38.1 Million0.0% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$36.6 Million0.69% of portfolio
-
Brown Capital Management LLC Baltimore, MD4.96MShares$27.3 Million0.74% of portfolio
-
State Street Corp Boston, MA4.08MShares$22.5 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $740M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...